Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, minerals and dietary supplements, feminine hygiene, diabetes care, scar management, and anti-parasite categories under the Good Sense, Sergeant's, Sentry, Zephrex D, PetArmor, and ScarAway brand names.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone353-1709-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.73 billion
Profitability
Miscellaneous
Employees10,600
Next Earnings Date11/6/2019 (Confirmed)
OptionableOptionable
Perrigo (NYSE:PRGO) Frequently Asked Questions
What is Perrigo's stock symbol?
Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."
How often does Perrigo pay dividends? What is the dividend yield for Perrigo?
Perrigo announced a quarterly dividend on Wednesday, July 31st. Stockholders of record on Friday, August 30th will be paid a dividend of $0.21 per share on Tuesday, September 17th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 1.55%. The ex-dividend date is Thursday, August 29th. View Perrigo's Dividend History.
How were Perrigo's earnings last quarter?
Perrigo Company PLC (NYSE:PRGO) released its earnings results on Thursday, August, 8th. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.05. The company earned $1.15 billion during the quarter, compared to analyst estimates of $1.13 billion. Perrigo had a return on equity of 9.57% and a net margin of 1.87%. Perrigo's revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.22 EPS. View Perrigo's Earnings History.
When is Perrigo's next earnings date?
How can I listen to Perrigo's earnings call?
Perrigo will be holding an earnings conference call on Wednesday, November 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Perrigo issued on next quarter's earnings?
Perrigo issued an update on its FY19 earnings guidance on Thursday, August, 8th. The company provided earnings per share guidance of $3.75-4.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.94.
What price target have analysts set for PRGO?
7 equities research analysts have issued twelve-month price objectives for Perrigo's stock. Their predictions range from $48.00 to $72.00. On average, they anticipate Perrigo's stock price to reach $56.71 in the next twelve months. This suggests a possible upside of 4.4% from the stock's current price. View Analyst Price Targets for Perrigo.
What is the consensus analysts' recommendation for Perrigo?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Perrigo.
Has Perrigo been receiving favorable news coverage?
Press coverage about PRGO stock has trended neutral on Wednesday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Perrigo earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Perrigo.
Who are some of Perrigo's key competitors?
Some companies that are related to Perrigo include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), The Medicines (MDCO), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).
What other stocks do shareholders of Perrigo own?
Who are Perrigo's key executives?
Perrigo's management team includes the folowing people:
- Mr. Murray S. Kessler, CEO, Pres & Director (Age 59)
- Mr. Todd W. Kingma, Exec. VP, Gen. Counsel & Sec. (Age 59)
- Mr. Jeffrey R. Needham, Exec. VP & Pres of Consumer Healthcare Americas (Age 63)
- Mr. Svend Andersen, Exec. VP & Pres of Consumer Healthcare International (Age 57)
- Mr. Ronald L. Winowiecki, Advisory (Age 53)
Who are Perrigo's major shareholders?
Perrigo's stock is owned by many different of retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.54%), Rhumbline Advisers (0.17%), State of Alaska Department of Revenue (0.08%), State of New Jersey Common Pension Fund D (0.08%), FTB Advisors Inc. (0.05%) and Commerzbank Aktiengesellschaft FI (0.04%). Company insiders that own Perrigo stock include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski, Murray S Kessler, Ronald Winowiecki, Svend Andersen, Theodore R Samuels II, Thomas Farrington, Todd W Kingma and Uwe Roehrhoff. View Institutional Ownership Trends for Perrigo.
Which institutional investors are selling Perrigo stock?
PRGO stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, CenturyLink Investment Management Co, Commerzbank Aktiengesellschaft FI, Brinker Capital Inc., Crossmark Global Holdings Inc. and Nisa Investment Advisors LLC. View Insider Buying and Selling for Perrigo.
Which institutional investors are buying Perrigo stock?
PRGO stock was purchased by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, State of Alaska Department of Revenue, Assenagon Asset Management S.A., FTB Advisors Inc., Rhumbline Advisers, Robeco Institutional Asset Management B.V., State of Michigan Retirement System and World Asset Management Inc. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Jeffrey C Smith, John Wesolowski, Murray S Kessler, Svend Andersen, Theodore R Samuels II, Todd W Kingma and Uwe Roehrhoff. View Insider Buying and Selling for Perrigo.
How do I buy shares of Perrigo?
Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Perrigo's stock price today?
One share of PRGO stock can currently be purchased for approximately $54.35.
How big of a company is Perrigo?
Perrigo has a market capitalization of $7.39 billion and generates $4.73 billion in revenue each year. The company earns $131 million in net income (profit) each year or $4.55 on an earnings per share basis. Perrigo employs 10,600 workers across the globe.View Additional Information About Perrigo.
What is Perrigo's official website?
How can I contact Perrigo?
Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]
MarketBeat Community Rating for Perrigo (NYSE PRGO)
MarketBeat's community ratings are surveys of what our community members think about Perrigo and other stocks. Vote "Outperform" if you believe PRGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
